On Monday, August 10, Harrow Health HROW will release its latest earnings report. Benzinga's outlook for Harrow Health is included in the following report.
Earnings and Revenue
Based on management's projections, Harrow Health analysts modeled for EPS of $-0.18 per share on sales of $5.70 million. In the same quarter last year, Harrow Health reported EPS of $-0.09 on revenue of $13.52 million. If the company were to report in-line earnings when it publishes results Monday, earnings would be down 100.0%. Sales would be down 51.57% from the year-ago period. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|
| EPS Estimate | -0.25 | 0.05 | -0.12 | -0.07 |
| EPS Actual | -0.50 | 0.10 | -0.26 | -0.09 |
| Revenue Estimate | 11.77 M | 13.66 M | 12.85 M | 12.78 M |
| Revenue Actual | 11.82 M | 12.60 M | 12.76 M | 13.52 M |
Stock Performance
Over the past 52-week period, shares of Harrow Health have declined 11.3%. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.
Don't be surprised to see the stock move on comments made during its conference call. Harrow Health is scheduled to hold the call at 17:00:00 ET and can be accessed here: https://www.webcaster4.com/Webcast/Page/2025/35615
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
